Valeant Pharma (VRX) Posts Strong Q3 Results, Bumps Outlook Higher; Aegis Capital Maintains at 'Buy'

October 20, 2014 9:55 AM

Aegis Capital affirms its Buy rating and $180 price target on Valeant Pharmaceuticals (NYSE: VRX) following Q3 results and guidance ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found